This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Phase 2 Study of Immunogenicity, Safety and Tolerability of CSL412 in Elderly Participants

This study has been completed.
Information provided by:
Seqirus Identifier:
First received: May 25, 2007
Last updated: July 17, 2016
Last verified: November 2008
Current influenza vaccines have a reduced efficacy in the elderly. This study will investigate the immunogenicity, safety and tolerability of an adjuvanted influenza vaccine in elderly participants.

Condition Intervention Phase
Influenza Biological: CSL412 Biological: Inactivated trivalent influenza vaccine Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Official Title: A Phase II, Double-Blind, Randomised, Controlled, Multi-Centre Study to Evaluate the Immunogenicity, Safety and Tolerability of Three Formulations of CSL412 in Adults (≥ 18 to ≤ 45 Years) and Older Adults (≥ 60 Years)

Resource links provided by NLM:

Further study details as provided by Seqirus:

Primary Outcome Measures:
  • seroprotection rate, HI titre & seroconversion/ significant increase
  • grade 3 or higher, vaccine associated fever or vaccine associated site ulceration, abscess or necrosis

Enrollment: 612
Study Start Date: May 2007
Study Completion Date: August 2007
Primary Completion Date: August 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Inactivated trivalent influenza vaccine
Biological: Inactivated trivalent influenza vaccine
Experimental: 2
CSL412 formulation
Biological: CSL412
Experimental: 3
CSL412 formulation
Biological: CSL412
Experimental: 4
CSL412 formulation
Biological: CSL412


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Aged ≥ 18 to ≤ 45 OR ≥ 60
  • Ability to provide pre-vaccination venous blood sample

Exclusion Criteria:

  • History of clinically significant medical conditions
  • Immunomodulative therapy
  • Acute infection
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00479648

United Kingdom
Chiltern International
Slough, United Kingdom
Sponsors and Collaborators
Principal Investigator: Elizabeth Hancox, Dr Chiltern International
  More Information

Responsible Party: Dr Russell Basser, CSL Limited Identifier: NCT00479648     History of Changes
Other Study ID Numbers: CSLCT-IIV-06-27
Study First Received: May 25, 2007
Last Updated: July 17, 2016

Additional relevant MeSH terms:
Immunologic Factors
Physiological Effects of Drugs processed this record on August 18, 2017